Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Eli Lilly Japan Looks at Double-Digit Growth Despite Large Price Cuts in 2 Mainstay Drugs: President Zulueta
March 16, 2012
- Teva-Kowa, Taiyo, Nippon Kayaku Apply for Approval of Gran Biosimilar
March 15, 2012
- Shionogi Submits Clinical Trial Application in Europe for OncoTherapy’s Cancer Vaccine
March 15, 2012
- Nichi-Iko Makes Yakuhan Its Subsidiary, Acquiring 69% of Company’s Stock
March 15, 2012
- Qol to Appoint Daiichi Sankyo Espha Chairman as Managing Director
March 15, 2012
- Nichi-Iko Announces New Med-Term Management Plan, Targets ¥130 Billion Sales in Mar 2016
March 15, 2012
- Baxter Reports Temporary Suspension in Shipments of Albumin Products to Japan
March 15, 2012
- MR Survey Shows Number of Doctors Visited, Detailing Activity Downtrend
March 14, 2012
- Pharmacists Rate Pfizer Highly for Generic Selection: Survey
March 14, 2012
- Nihon Chouzai to Provide Generic Drug Information System to Pharmacies of Other Companies
March 14, 2012
- Astellas and UMN Announce Favorable Phase II Results for Influenza HA Vaccine
March 14, 2012
- Sawai’s Next Midterm Management Plan Aims to Create a “Muscular Company”: Pres. Sawai
March 14, 2012
- MediciNova Obtains Notice of Patent Allowance for Ibudilast for Treatment of Chronic Neuropathic Pain
March 14, 2012
- Pfizer Reports 19% Boost in Sales in FY2011, “Continued Growth Possible” After Re-Pricing
March 13, 2012
- Upcoming Reforms “Ideal” for Promoting Use of Generic Drugs: President Sawai of Sawai Pharm.
March 13, 2012
- Nippon Shinyaku and Taiho to Cancel Licensing Agreement for Novel Antipruritic Agent
March 12, 2012
- UMN, IHI Start Construction of Biopharmaceutical Manufacturing Plant
March 12, 2012
- Novartis to Transfer Zaditen Ophthalmic Solution Marketing Rights to Alcon Japan
March 12, 2012
- Sosei Initiates PI Trial for Oropharyngeal Candidiasis Treatment SO-1105
March 12, 2012
- Taiyo to Discontinue Marketing Around 50 Products; Started Notifying Customers Last May
March 12, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…